THE ULTIMATE GUIDE TO TRACLEER

6 The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV in the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) including bosentan, sitaxentan and ambrisentan are oral therapies accredited to be used in PAH. As no oral agent has shown superiority there stays discussion as to which needs to be used ver